SPARC is working on L731, which is a highly selective and potent LTD4 antagonist.
LTD4 receptor plays an important role in pathogenesis of asthma and nasal allergies. The preclinical profile of Sun-L731 shows that it is very potent and selective entity for antagonist; with a good oral bioavailability. It is a 10-times more potent compared to Montelukast. In preclinical models we have found that we have better efficacy and better duration of action when compared to Montelukast. Its onset of action is faster than Montelukast and there are no safety issues, that it has a very high therapeutic index.
Currently, this product is in preclinical stage and SPARC is preparing for IND filing by conducting safety
pharmacology studies as well as toxicology studies. SPARC plans to file a clinical trial application in UK in Q1FY16.